Paige Britt

The risk of pain deterioration was similar with T-DXd/pertuzumab vs standard of care in the DESTINY-Breast09 trial.

Estrogen alone was associated with a lower risk of BRCA-mutated breast cancer, according to data from an ongoing study.

The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.

Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.